ClinicalTrials.gg
CompletedNCT01860989Updated Sep 10, 2015Results posted

A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection

A Phase 2 interventional study of KAE609 and KAE609 in Cure Rate, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in 2 countries. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2015-09-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with acute P. falciparum infection after single dose with KAE609 at 75 mg, 150mg, 225mg and 300mg/day

Read the detailed description

the study is comprised of 4 sequential cohorts, in total there will be up to 48 patients enrolled in the study.

cohort 1: 6-12 patients receive 75mg single dose. cohort 2: 6-12 patients receive 150mg single dose. cohort 3: 6-12 patients receive 225mg single dose. cohort 4: 6-12 patients receive 300mg single dose. After approximately every 6 patients in any cohort have been treated with a given dose and complete the first 15 days, a safety and tolerability data review will be conducted by a Data Monitoring Committee(DMC). Consensus agreement of DMC is required to either escalate to the next dose level or expand a given cohort with an additional 6 patients in order to obtain more safety data.

02

Conditions studied

  • Cure Rate

Browse trials for

Keywords

  • parasitemia
03

In context

Parasitemia

23 studies on the registry are indexed under Parasitemia; 2 are open to participants now.

This study's enrollment of 11 is below the median of 64 across 15 interventional studies indexed under Parasitemia.

Browse Parasitemia studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged 20 to 60 years
  • Presence of mono-infection of P. falciparum
  • Weight between 40 kg to 90 kg

Exclusion criteria

Exclusion Criteria:

  • Patients with signs and symptoms of severe/complicated malaria
  • Mixed Plasmodium infection
  • Presence of other serious or chronic clinical condition requiring hospitalization.
  • Severe malnutrition
  • Significant chronic medical conditions which in the opinion of the investigator preclude enrollment into the study
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Cohort 1

    6-12 subjects with Plasmodium falciparum malaria will receive 75 mg KAE609 as a single dose

    Drug: KAE609

  • Experimental
    Cohort 2

    6-12 subjects with Plasmodium falciparum malaria will receive 150 mg KAE609 as a single dose

    Drug: KAE609

  • Experimental
    Cohort 3

    6 to 12 subjects with Plasmodium falciparum malaria will receive 225 mg KAE609 as a single dose

    Drug: KAE609

  • Experimental
    Cohort4

    6- 12 subjects with Plasmodium falciparum malaria will receive 300 mg KAE609 as a single dose

    Drug: KAE609

Interventions

  • DrugKAE609

    KAE609 75mg single dose

  • DrugKAE609

    KAE609 150mg single dose

  • DrugKAE609

    KAE609 225mg single dose

  • DrugKAE609

    KAE609 300mg single dose

06

What researchers measure

Primary outcomes

  1. 28-day Cure Rate

    28-day cure rate was measured by the endpoint of complete cure without recrudescence before Day 29. The primary variable of 28-day cure rate was defined as the proportion of patients with clearance of asexual parasitemia (by blood film) by day 6 of the study, and without subsequent recrudescence (by blood film).

    Time frame: Day 28

07

Results

Posted Sep 3, 2015

Participant flow

Participant flow — Overall Study
MilestoneTotal - Cohort 1
Started11
Completed6
Not completed5
Withdrew: Unsatisfactory therapeutic5

Outcome measures

Primary28-day Cure Rate

28-day cure rate was measured by the endpoint of complete cure without recrudescence before Day 29. The primary variable of 28-day cure rate was defined as the proportion of patients with clearance of asexual parasitemia (by blood film) by day 6 of the study, and without subsequent recrudescence (by blood film).

Time frame:
Day 28
Reported as:
Number · Percentage of participants
28-day Cure Rate
Percentage of participantsTotal - Cohort 1
28-day Cure Rate63.67

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Total - Cohort 1—3/11 (27.3%)8/11 (72.7%)
Most frequent serious events
Most frequent serious events
EventTotal - Cohort 1
Alanine aminotransferase increasedInvestigations2/11
JaundiceHepatobiliary disorders1/11
Aspartate aminotransferase increasedInvestigations1/11
Most frequent other events
Showing 10 of 25
Most frequent other events
EventTotal - Cohort 1
Platelet count decreasedInvestigations7/11
Alanine aminotransferase increasedInvestigations5/11
Aspartate aminotransferase increasedInvestigations4/11
ArthralgiaMusculoskeletal and connective tissue disorders4/11
NauseaGastrointestinal disorders3/11
HeadacheNervous system disorders3/11
FatigueGeneral disorders2/11
Blood alkaline phosphatase increasedInvestigations2/11
DizzinessNervous system disorders2/11
CoughRespiratory, thoracic and mediastinal disorders2/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)Total - Cohort 1
Mean31.6 ± 7.50
Sex: Female, Male
Sex: Female, Male(Participants)Total - Cohort 1
Female0
Male11
08

Study locations

4 sites
  • Novartis Investigative Site
    Ratchabari, 70180, Thailand
  • Novartis Investigative Site
    Srisaket, 33140, Thailand
  • Novartis Investigative Site
    Tak, 63140, Thailand
  • Novartis Investigative Site
    Hanoi, 10000, Vietnam
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2013
First posted
May 23, 2013
Start
Jul 2013
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Sep 3, 2015
Last update
Sep 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01860989
Responsible party
Sponsor
First posted
May 23, 2013
Start date
Jul 2013
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Sep 3, 2015
Last update
Sep 10, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NITD 609

Start the discussion